000277426 001__ 277426
000277426 005__ 20250323000946.0
000277426 0247_ $$2doi$$a10.1001/jamapsychiatry.2024.4305
000277426 0247_ $$2pmid$$apmid:39841452
000277426 0247_ $$2pmc$$apmc:PMC11883504
000277426 0247_ $$2ISSN$$a2168-622X
000277426 0247_ $$2ISSN$$a0003-990X
000277426 0247_ $$2ISSN$$a0375-8532
000277426 0247_ $$2ISSN$$a1538-3636
000277426 0247_ $$2ISSN$$a2168-6238
000277426 0247_ $$2ISSN$$a2330-9636
000277426 0247_ $$2altmetric$$aaltmetric:173257015
000277426 037__ $$aDZNE-2025-00409
000277426 041__ $$aEnglish
000277426 082__ $$a610
000277426 1001_ $$aWiels, Wietse A$$b0
000277426 245__ $$aDepressive Symptoms and Amyloid Pathology.
000277426 260__ $$aChicago, Ill.$$bAMA$$c2025
000277426 3367_ $$2DRIVER$$aarticle
000277426 3367_ $$2DataCite$$aOutput Types/Journal article
000277426 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1742377671_22879
000277426 3367_ $$2BibTeX$$aARTICLE
000277426 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277426 3367_ $$00$$2EndNote$$aJournal Article
000277426 520__ $$aDepressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology.To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia.Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024.Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms.In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI.Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumulation may commonly underlie depressive symptoms in late life.
000277426 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000277426 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277426 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000277426 650_7 $$2NLM Chemicals$$aBiomarkers
000277426 650_7 $$2NLM Chemicals$$aPeptide Fragments
000277426 650_7 $$2NLM Chemicals$$aamyloid beta-protein (1-42)
000277426 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000277426 650_2 $$2MeSH$$aHumans
000277426 650_2 $$2MeSH$$aFemale
000277426 650_2 $$2MeSH$$aMale
000277426 650_2 $$2MeSH$$aAged
000277426 650_2 $$2MeSH$$aDepression
000277426 650_2 $$2MeSH$$aMiddle Aged
000277426 650_2 $$2MeSH$$aCross-Sectional Studies
000277426 650_2 $$2MeSH$$aCognitive Dysfunction
000277426 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000277426 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000277426 650_2 $$2MeSH$$aPositron-Emission Tomography
000277426 650_2 $$2MeSH$$aAged, 80 and over
000277426 650_2 $$2MeSH$$aAdult
000277426 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000277426 650_2 $$2MeSH$$aPeptide Fragments: cerebrospinal fluid
000277426 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000277426 650_2 $$2MeSH$$aAge Factors
000277426 693__ $$0EXP:(DE-2719)DIAN-20090101$$5EXP:(DE-2719)DIAN-20090101$$eLongitudinal Study on Dominantly Inherited Alzheimer's Disease$$x0
000277426 7001_ $$aOomens, Julie E$$b1
000277426 7001_ $$aEngelborghs, Sebastiaan$$b2
000277426 7001_ $$aBaeken, Chris$$b3
000277426 7001_ $$avon Arnim, Christine A F$$b4
000277426 7001_ $$aBoada, Mercè$$b5
000277426 7001_ $$aDidic, Mira$$b6
000277426 7001_ $$aDubois, Bruno$$b7
000277426 7001_ $$aFladby, Tormod$$b8
000277426 7001_ $$avan der Flier, Wiesje M$$b9
000277426 7001_ $$aFrisoni, Giovanni B$$b10
000277426 7001_ $$aFröhlich, Lutz$$b11
000277426 7001_ $$aGill, Kiran Dip$$b12
000277426 7001_ $$aGrimmer, Timo$$b13
000277426 7001_ $$aHildebrandt, Helmut$$b14
000277426 7001_ $$aHort, Jakub$$b15
000277426 7001_ $$aItoh, Yoshiaki$$b16
000277426 7001_ $$aIwatsubo, Takeshi$$b17
000277426 7001_ $$aKlimkowicz-Mrowiec, Aleksandra$$b18
000277426 7001_ $$aLee, Dong Young$$b19
000277426 7001_ $$aLleó, Alberto$$b20
000277426 7001_ $$aMartinez-Lage, Pablo$$b21
000277426 7001_ $$ade Mendonça, Alexandre$$b22
000277426 7001_ $$aMeyer, Philipp T$$b23
000277426 7001_ $$aKapaki, Elisabeth N$$b24
000277426 7001_ $$aParchi, Piero$$b25
000277426 7001_ $$aPardini, Matteo$$b26
000277426 7001_ $$aParnetti, Lucilla$$b27
000277426 7001_ $$aPopp, Julius$$b28
000277426 7001_ $$aRami, Lorena$$b29
000277426 7001_ $$aReiman, Eric M$$b30
000277426 7001_ $$aRinne, Juha O$$b31
000277426 7001_ $$aRodrigue, Karen M$$b32
000277426 7001_ $$aSánchez-Juan, Pascual$$b33
000277426 7001_ $$aSantana, Isabel$$b34
000277426 7001_ $$aSarazin, Marie$$b35
000277426 7001_ $$aScarmeas, Nikolaos$$b36
000277426 7001_ $$aSkoog, Ingmar$$b37
000277426 7001_ $$aSnyder, Peter J$$b38
000277426 7001_ $$aSperling, Reisa A$$b39
000277426 7001_ $$aVilleneuve, Sylvia$$b40
000277426 7001_ $$aWallin, Anders$$b41
000277426 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b42$$udzne
000277426 7001_ $$aZetterberg, Henrik$$b43
000277426 7001_ $$aOssenkoppele, Rik$$b44
000277426 7001_ $$aVerhey, Frans R J$$b45
000277426 7001_ $$aVos, Stephanie J B$$b46
000277426 7001_ $$aVisser, Pieter Jelle$$b47
000277426 7001_ $$aJansen, Willemijn J$$b48
000277426 7001_ $$agroup, Amyloid Biomarker Study$$b49$$eCollaboration Author
000277426 7001_ $$aInitiative, Alzheimer’s Disease Neuroimaging$$b50$$eCollaboration Author
000277426 7001_ $$aAlcolea, Daniel$$b51
000277426 7001_ $$aAltomare, Daniele$$b52
000277426 7001_ $$aBaiardi, Simone$$b53
000277426 7001_ $$aBaldeiras, Ines$$b54
000277426 7001_ $$aBateman, Randall J$$b55
000277426 7001_ $$aBlennow, Kaj$$b56
000277426 7001_ $$aBottlaender, Michel$$b57
000277426 7001_ $$aden Braber, Anouk$$b58
000277426 7001_ $$avan Buchem, Mark A$$b59
000277426 7001_ $$aByun, Min Soo$$b60
000277426 7001_ $$aCerman, Jirí$$b61
000277426 7001_ $$aChen, Kewei$$b62
000277426 7001_ $$aChipi, Elena$$b63
000277426 7001_ $$aDay, Gregory S$$b64
000277426 7001_ $$0P:(DE-2719)2811239$$aDrzezga, Alexander$$b65$$udzne
000277426 7001_ $$aEckerström, Marie$$b66
000277426 7001_ $$aEkblad, Laura L$$b67
000277426 7001_ $$aEpelbaum, Stéphane$$b68
000277426 7001_ $$aFörster, Stefan$$b69
000277426 7001_ $$aFortea, Juan$$b70
000277426 7001_ $$aFreund-Levi, Yvonne$$b71
000277426 7001_ $$aFrings, Lars$$b72
000277426 7001_ $$aGuedj, Eric$$b73
000277426 7001_ $$aHausner, Lucrezia$$b74
000277426 7001_ $$aHellwig, Sabine$$b75
000277426 7001_ $$aHuey, Edward D$$b76
000277426 7001_ $$aJiménez-Bonilla, Julio F$$b77
000277426 7001_ $$aJohnson, Keith A$$b78
000277426 7001_ $$aJuaristi, Ane Iriondo$$b79
000277426 7001_ $$aKandimalla, Ramesh$$b80
000277426 7001_ $$aParaskevas, George$$b81
000277426 7001_ $$aKern, Silke$$b82
000277426 7001_ $$aKirsebom, Bjørn-Eivind S$$b83
000277426 7001_ $$aKornhuber, Johannes$$b84
000277426 7001_ $$aLagarde, Julien$$b85
000277426 7001_ $$aLandau, Susan M$$b86
000277426 7001_ $$aLegdeur, Nienke$$b87
000277426 7001_ $$aLlibre Guerra, Jorge J$$b88
000277426 7001_ $$aMaserejian, Nancy N$$b89
000277426 7001_ $$aMarquié, Marta$$b90
000277426 7001_ $$aMinatani, Shinobu$$b91
000277426 7001_ $$aMorbelli, Silvia Daniela$$b92
000277426 7001_ $$aMroczko, Barbara$$b93
000277426 7001_ $$aNtanasi, Eva$$b94
000277426 7001_ $$ade Oliveira, Catarina Resende$$b95
000277426 7001_ $$aOlivieri, Pauline$$b96
000277426 7001_ $$aOrellana, Adelina$$b97
000277426 7001_ $$aPerrin, Richard J$$b98
000277426 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b99$$udzne
000277426 7001_ $$aPrabhakar, Sudesh$$b100
000277426 7001_ $$aRamakers, Inez H$$b101
000277426 7001_ $$aRodríguez-Rodriguez, Eloy$$b102
000277426 7001_ $$aRuiz, Agustín$$b103
000277426 7001_ $$aRüther, Eckart$$b104
000277426 7001_ $$aSelnes, Per$$b105
000277426 7001_ $$aSilva, Dina$$b106
000277426 7001_ $$aSoininen, Hilkka$$b107
000277426 7001_ $$aSpiru, Luiza$$b108
000277426 7001_ $$aTakeda, Akitoshi$$b109
000277426 7001_ $$aTeichmann, Marc$$b110
000277426 7001_ $$aTijms, Betty M$$b111
000277426 7001_ $$aTeunissen, Charlotte E$$b112
000277426 7001_ $$aThompson, Loisa I$$b113
000277426 7001_ $$aVogelgsangs, Jonathan$$b114
000277426 7001_ $$0P:(DE-2719)2811820$$aVöglein, Jonathan$$b115$$udzne
000277426 7001_ $$aWaldemar, Gunhild$$b116
000277426 7001_ $$aWallin, Åsa K$$b117
000277426 7001_ $$aYannakoulia, Mary$$b118
000277426 7001_ $$aYi, Dahyun$$b119
000277426 7001_ $$aZettergren, Anna$$b120
000277426 773__ $$0PERI:(DE-600)2698864-1$$a10.1001/jamapsychiatry.2024.4305$$gVol. 82, no. 3, p. 296 -$$n3$$p296 - 310$$tJAMA psychiatry$$v82$$x2168-622X$$y2025
000277426 909CO $$ooai:pub.dzne.de:277426$$pVDB
000277426 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811317$$aExternal Institute$$b42$$kExtern
000277426 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811239$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b65$$kDZNE
000277426 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811024$$aExternal Institute$$b99$$kExtern
000277426 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811820$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b115$$kDZNE
000277426 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000277426 9141_ $$y2025
000277426 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJAMA PSYCHIAT : 2022$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-13
000277426 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bJAMA PSYCHIAT : 2022$$d2024-12-13
000277426 9201_ $$0I:(DE-2719)1011202$$kAG Boecker$$lPositron Emissions Tomography (PET)$$x0
000277426 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000277426 980__ $$ajournal
000277426 980__ $$aVDB
000277426 980__ $$aI:(DE-2719)1011202
000277426 980__ $$aI:(DE-2719)1111015
000277426 980__ $$aUNRESTRICTED